Surrozen Q3 net loss widens 81% year over year to $129.72 million
SRZN•Surrozen's third-quarter 2026 net loss widened 81% year over year to $129.72 million, with no revenue recorded. October financing generated approximately $118.9 million in net proceeds, extending anticipated cash runway into 2029.
1. Quarterly results and updates
Surrozen reported a third-quarter 2026 net loss of $129.72 million, up 81% year over year, and no revenue, compared with $983,000 in the year-earlier quarter. October financing generated approximately $118.9 million in net proceeds, extending anticipated cash runway into 2029. The first patient received SZN-8141 in DUET Phase 1b; planned Phase 2a enrollment expanded from approximately 60 to 150 patients. DUET Phase 1b topline data are expected in the second half of 2027, with Phase 2a results expected in 2028.
